preview

Property Rights Of Cells

Good Essays

The repercussions of defining who has ownership of cells will also immediately affect the families of those individuals whose cells were extracted and future generations. Currently, families have not been compensated for the use of the family member’s cells for medical research and pharmaceutical productions. As previously mentioned, Lacks’s family has not been given any financial compensation for the multiple distributions and pharmaceutical developments made from Lacks’s tumor cells. They have been given several acknowledgements and Lacks was given several awards for her cell’s contribution. These “benefits” do not have monetary value, allowing for the multiple institutions that have made billions to continue to reap in the benefits of …show more content…

This advocates for the use of broad or blanket consent. “This empowers researchers or keepers of the data or tissues to use the material in any way they see fit with no conditions applied” (Bahadur 2004). The only course of action patients have, to obtain any monetary compensation is to sue on the grounds of lack of informed consent. This is due to researchers arguing that they are not capable of exploiting the patient since experimentation on an extracted cell does not harm or alter the health of the patient. This is evident in both Lacks’ and Moore’s cases, where both individual received “recognition” for their contribution and not fiscal compensation.
If researchers and institutions have complete control over cells once extracted, then research and understanding of medicine, pharmacodynamics, pharmacokinetics, metabolism, and genetic markers can significantly advance. Currently, courts have favored this course of action, as demonstrated in Moore v. Regents of the University of California. Additionally, there are no property rights in corpuses (Yang, Y et al 2011). This advocates for the continuation for the asymmetrical power given towards researchers and large biotech companies. This would benefit researchers, large research institutions and their contributors, and pharmaceutical companies while discriminating the patient’s right to know what occurs to their genetic information, the most personal aspect that makes them human. The consequence

Get Access